


# Author's Accepted Manuscript

Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic review

Carmelo Pirone, Claudia Mendoza-Pinto, Daniëlle A. van der Windt, Ben Parker, Miriam O'Sullivan, Ian N. Bruce



PII: S0049-0172(17)30099-9  
DOI: <http://dx.doi.org/10.1016/j.semarthrit.2017.04.010>  
Reference: YSARH51190

To appear in: *Seminars in Arthritis and Rheumatism*

Cite this article as: Carmelo Pirone, Claudia Mendoza-Pinto, Daniëlle A. van der Windt, Ben Parker, Miriam O'Sullivan and Ian N. Bruce, Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic review, *Seminars in Arthritis and Rheumatism*, <http://dx.doi.org/10.1016/j.semarthrit.2017.04.010>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

# **Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): a systematic review**

**\*Carmelo Pirone<sup>1</sup>**

<sup>1</sup> Department of Internal Medicine and Medical Specialties Rheumatology Unit Sapienza University of Rome; Rome, Italy

pirone.carmelo@gmail.com

**\*Claudia Mendoza-Pinto<sup>2</sup>**

<sup>2</sup> Systemic Autoimmune Disease Research Unit, Regional General Hospital 36-CIBIOR, Mexican Institute for Social Security; Puebla, México

cmp\_26@yahoo.com.mx

**Daniëlle A. van der Windt<sup>3</sup>**

<sup>3</sup> Arthritis Research UK Primary Care Centre, Research Institute for Primary Care & Health Sciences, Keele University; Keele, Staffordshire, UK

d.van.der.windt@keele.ac.uk

**Ben Parker<sup>4,5</sup>**

<sup>4</sup> NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre; Manchester, UK

<sup>5</sup> Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Oxford Road, Manchester, UK

Benjamin.Parker@manchester.ac.uk

**Miriam O'Sullivan**<sup>4</sup>

<sup>4</sup> NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre; Manchester, UK

miriam.o'sullivan@manchester.ac.uk

**Ian N. Bruce**<sup>4,6</sup>

<sup>4</sup> NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre; Oxford Road, Manchester, UK

<sup>6</sup> Arthritis Research UK Centre for Epidemiology, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Oxford Road, Manchester, UK

ian.bruce@manchester.ac.uk

\*Both authors contributed equally to this manuscript preparation

### **Corresponding author**

Prof. Ian Bruce

Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK.

E-mail: ian.bruce@manchester.ac.uk

**Keywords:** Systemic lupus erythematosus, rituximab, systematic review, prognosis

**Conflict of interest**

The University of Manchester received unrestricted grants from Roche and GSK to establish and continue the British Isles Lupus Assessment Group Biologics Register for which Professor Bruce is Chief Investigator and Dr Parker is a co-investigator.

The authors declare no other conflicts of interest.

**ABSTRACT**

**Background:** The clinical outcomes following rituximab (RTX) treatment in patients with SLE is highly variable. We aimed to identify predictive and prognostic factors associated with RTX therapy outcomes in patients with SLE.

**Methods:** Studies in adults and paediatric patients with SLE were included. We included randomized clinical trials (RCTs) for predictors of differential treatment effect and cohort studies for potential prognostic factors in patients treated with RTX (global clinical, cutaneous and renal either response or relapse and side effects). Methodological quality was assessed using Cochrane Collaboration Risk of Bias tool and the Quality In Prognosis Studies Tool (QUIPS) for RCTs and cohort studies, respectively. The quality of subgroup analyses testing predictors of differential treatment response was also evaluated. A best evidence synthesis was performed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework.

**Results:** Sixteen articles were included (3 from 2 RCTs and 13 from 6 cohort studies). The overall quality of evidence (QoE) was low to very low (GRADE framework). QoE for predictive factors based on RCTs analysing sociodemographic variables, was rated very low due lack interaction tests, limited power of subgroup analyses, study limitations and imprecisions. Disease-related factors including clinical phenotype and severity, baseline anti-

ENA antibodies and anti-Ro antibodies, interleukin (IL) 2/21 single nucleotide polymorphism (SNP), as well as post-RTX complete B cell depletion and earlier B cell repopulation showed some evidence for prognostic value, but were rated low to very low QoE because of early phase of investigation (exploratory analysis), insufficient adjustment for confounding in most studies, high risk of bias, inconsistency and imprecisions.

**Conclusions:** To date studies addressing prognostic factors are hypothesis generating and cannot be used to make any specific recommendations for routine clinical practice. A number of potential predictors/prognostic factors were identified which require to be validated as being specific for response to RTX therapy and to enable more personalised use of this agent.

## 1. INTRODUCTION

Personalised medicine research is emerging across a number of medical disciplines [1] and if successful will enable us to move from “all comer” or “empirical” medicine to a more targeted approach thus making the best decisions for individuals or groups of similar patients [2;3]. A stratified medicine approach requires testing of patients for the presence of factors considered predictive of an improved treatment response (more benefit, less harm, or both) compared to other (active) treatment options. Thus, the ability to target optimal therapy to the right patient will have an impact on healthcare delivery, quality and costs of care.

SLE is an autoimmune disease characterized by loss of tolerance to nucleic acids and highly diverse clinical manifestations [4]. B cell depletion with the anti-CD20 monoclonal rituximab (RTX) has been found to be effective in a number of autoimmune conditions including rheumatoid arthritis (RA) [5]. Successful use of RTX in patients with SLE has been reported in a number of open-label cohorts studies [6] and a recent meta-analysis supported its effectiveness in refractory SLE [7]. Two RCTs of RTX in patients with SLE (EXPLORER [8] and LUNAR [9]) did not however achieve their primary end points. Some researchers

have cogently argued that various aspects of trial design could account for these apparent failures [6]. RTX is therefore now an established drug used in the treatment of SLE and its use is supported in several guidelines [10;11]. However, variability in biological and/or clinical response to RTX has been reported in a number of studies [12;13]. In addition to study design issues, heterogeneity of the SLE population is also likely to contribute to these variable results, suggesting a single therapy or therapeutic approach may not be equally effective in all patients with SLE. A better understanding of why some patients respond better than others to RTX and in particular which factors are associated with better responses (or more adverse events) is therefore important to optimize and better target the use of this therapy to improve patient outcomes.

The objectives of this systematic review therefore were: (1) to identify predictors of differential response (moderators) to RTX therapy for SLE in RCTs; and (2) to identify prognostic factors associated with outcomes following RTX therapy in cohort studies of patients with SLE.

## **2. METHODS**

### **2.1 Literature search**

Studies were identified through a systematic literature search in the following databases: MEDLINE via Ovid (1946 to December 2015), EMBASE via Ovid (1974 to December 2015), The Cochrane Central Register of Randomized Controlled Trials (CENTRAL-The Cochrane Library) via Ovid (to December 2015) and Web of Science (to December 2015). Additional studies were identified through a review of the included studies' reference lists. To ensure proper interpretation of the results by our team, publication language was restricted

to English, Italian or Spanish. The search strategies used for Ovid MEDLINE® and applied to other databases in the literature are available in Supplementary file A, Table A.1.

## 2.2 Selection criteria

Publications were included in the review if they met the following inclusion criteria: (1) RCTs and quasi-randomized studies in all different phases that compared RTX therapy versus control in SLE patients, (2) Prospective or retrospective cohort studies, which have included at the beginning of follow up not less than 30 patients. We decide to include observational cohorts with a minimum of 30 patients in our systematic review because, for prognostic factors, there are accepted methods for calculating the sample size for binary or continuous outcomes [14], and if confounding factors also are considered, smaller sample size would have been irrelevant for our purposes. We also excluded review articles, opinion papers, letters to the editor, case reports, case series or conference abstracts. RCTs or cohort studies reporting outcomes for RTX therapy as a combination therapy with immunosuppressant agents (except when RTX was added to previous stable dose treatment) were also excluded.

## 2.3 Study screening

References and abstracts identified by the search were imported into Reference Manager (RefMan) Version 12 and duplicates were removed. The resulting titles and abstracts were, independently, reviewed by CP and CMP. If titles and abstract did not give enough information to judge eligibility, full manuscripts were procured and independently reviewed by two reviewers (CP and CMP). The full text of each article was then tested against all inclusion and exclusion criteria. The review team made every effort to identify multiple publications from a single study to obtain all relevant information from trials and cohorts.

Disagreements regarding eligibility were resolved through discussion or by a third reviewer (INB or BP) if necessary. The bibliographies of all included studies were manually screened for additional articles of interest.

## **2.4 Data extraction**

Standardised data extraction forms were used to extract the following study details for RCTs: author identification, year of publication, setting, number of patients included, intervention and control treatment including dose and administration details, duration of follow-up, differential treatment predictors or subgroups analysis and relevant outcomes; and for prognostic cohort studies: study design, setting, study duration, number of patients included, prognostic factors, relevant outcomes and adjustment for confounders. Definitions for prognostic factors or outcomes were taken from the included publications (Supplementary file A, Table A.2). Data extraction was done independently by 2 reviewers (CP and CMP). When available, estimates of treatment effects for patient subgroups in RCTs, and associations of prognosis factors with treatment outcome in cohorts were extracted from each published report. Where insufficient information on these estimates was provided in original reports, where possible we used available data to calculate relative risks and corresponding 95% confidence interval (95% CI) using methods recommended in the Cochrane Handbook for Systematic Reviews of interventions [15]. Moderators or prognostic factors had to have been measured either at baseline or during RTX therapy.

## **2.5 Methodological quality assessment**

In accordance with PRISMA guidelines we assessed methodological quality of included studies [16]. The methods used in this for quality appraisal are described in detail elsewhere



[17], but in short, the Cochrane risk of bias tool [18-20] was used for RCTs, while the Quality In Prognosis Studies Tool was used to assess risk of bias in cohort studies (Supplementary file A, table A.3). The quality of subgroup (moderation) analyses in RCTs was also evaluated using criteria proposed by Pincus et al [19]. Two reviewers (CMP and MOS) independently rated the methodological quality of the selected studies. The two reviewers discussed disagreement about whether a criterion was met, which were resolved by consensus.

## 2.6 Data synthesis

Due to the expected heterogeneity of selected studies, we performed a narrative best evidence synthesis to summarize evidence for potential predictors from RCTs and prognostic factors from cohort studies, which takes into account the strength of the association and the methodological quality of the studies. We identified 3 PICO (Population, Intervention, Comparator, Outcome) questions [21] regarding potential predictors of the effect of RTX and 4 PICO questions regarding prognostic factors to structure the evidence synthesis. The overall quality of evidence (QoE) was assessed for each PICO question for RCTs using GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) for RCTs [22] and the GRADE adaptation for prognostic evidence [23] (Supplementary file A, Table A.4). The PICO comparison (C) category was not applicable and dropped for cohort studies.

We used Review Manager (RevMan) to summarize the data and GRADE profiler (GRADEpro) software to produce the GRADE profile [24]. More details about GRADE evaluation can be found elsewhere (Supplementary file A, Tables A.5 and A.6) [17].

### 3. RESULTS

#### 3.1 Literature search

The electronic searches resulted in 734 records after exclusion of duplicates, and 94 full articles were assessed for eligibility (see PRISMA flow chart, Figure 1). A total of 16 articles met the eligibility criteria and were included in the review (3 papers from 2 RCTs and 13 papers from 6 cohort studies). A list of excluded studies and the reason for exclusion are available in Supplementary file A, Table A.7).


#### 3.2 Study characteristics

The characteristics of the included studies are given in Tables 1 and 2 (RCTs and cohort studies respectively). We included analyses from 2 RCTs [8;9], one of which was reported in a separate secondary paper with a biomarker endpoint [25]. One RCT reported on multiple potential predictors of the effect of RTX [8]. From two RCTs, we extracted data only in the RTX arm when specific possible predictors for this therapy were only examined in this group; we displayed these results in the tables for prognostic factors used in cohort studies [9;25].

Across RCTs and cohorts five studies included participants aged 15–17 years [8;9;26-28], while seven studies only included patients  $\geq 18$  years [29-33]. In five studies, mean age was not reported [13;34-37]. The follow-up duration varied from 24-78 weeks (6-18 months) for RCTs and 6-60 months for cohort studies. One RCT (or subgroup analyses) included only patients with active LN [9] and one evaluated patients with extra-renal manifestations [8]. Two cohort studies took into account active LN [9;28;32], one study evaluated mucocutaneous either response or flare [37] and the remaining studies analysed global

clinical response or relapse. No cohort studies were identified that described the association of sociodemographic factors with outcomes in SLE patients with RTX (PICO 4).

**Figure 1** Study flow diagram detailing the literature search



**Table 1** Characteristics of RCTs evaluating the effectiveness of rituximab in patients with SLE

Study ID	PICO	Setting	Population	No. patients	Intervention	Follow-up	Possible Predictor	Outcomes
Merriell et al. [8]*	1 2 3	International	Moderately-to-Severely Active SLE	257	Rituximab 1,000 mg (n= 169) or placebo (n= 88) on days 1, 15, 168, and 182.	52 w 78 w	Age Gender Race Assigned prednisone dose Background immunosuppressant Duration of lupus Baseline BILAG A score Baseline BILAG-defined mucocutaneous or musculoskeletal system involvement	Major clinical response Partial clinical response Overall response No response
Rovin et al. [9]	3	International	LN III, IV	144	Rituximab 1 g on d 1, 15, 168, 182 + MMF 3 g/d (n= 72) or MMF (3 g/d) (n= 72)	52 w 78 w	B cells at baseline B cells depletion	Overall response
Tew et al. [25]*	3	International	Moderately-to-Severely Active SLE	257	Rituximab 1,000 mg (n=169) or placebo (n= 88) on days 1, 15, 168, and 182	52 w	Autoantibodies B cells levels Interferon signature	Normalization of complement and anti-dsDNA

Studies are listed in alphabetical order. \* multiple papers on partially the same trial cohort HACA, human antichimeric antibody; IVC, intravenous cyclophosphamide; LN, lupus nephritis; MMF, mycophenolate mofetil; PICO, Population, Intervention, Comparator, Outcome (number of PICO question); RCT, randomized clinical trial; w, weeks.

**Table 2** Characteristics of studies on prognostic factors

Study ID	Setting	PICO	Design	No. patients	Dose of rituximab	Follow-up	Possible Predictor	Outcomes	Adjustment for confounders
Carter et al. [26] ¥	UK	7	Retrospective cohort	35	1 g x 2 plus 750 mg IVC	66 w‡	Serum BAFF levels	Clinical Relapse Changes in B cells High anti-dsDNA	Not indicated
Catapano et al. [29]	UK	7	Retrospective cohort	31	375 mg/m <sup>2</sup> /week x 4 or 1000 mg x 2	30 m‡	Serologic features	Response Relapse	Not indicated
Dias et al. [30] ¥	UK	7	Retrospective cohort	98	1 g x 2 plus 750 mg IVC	5 y†	Longer duration of BCD	Clinical improvement	Sociodemographic, clinical and serological features
Fernandez-Nebro et al. [31]	Spain	6	Retrospective cohort	116	375 mg/m <sup>2</sup> /week x 4 or 1000 mg x 2	20 m†	Disease related variables	Clinical response Adverse events	Sociodemographic, clinical and treatment variables
Jónsdóttir et al. [32] *¥	International	6	Retrospective cohort	43	375 mg/m <sup>2</sup> /week x 4 or 1000 mg x 2 plus 500-1000 mg IVC	6 m	LN histopathological class	Renal improvement	Not indicated
Lazarus et al. [27] ¥	UK	7	Retrospective cohort	61	1 g of rituximab x 2 plus 750 mg IVC	52 w	Anti-dsDNA antibody levels at baseline  B cell repopulation	Clinical relapse	Not indicated

Lindholm et al. [28]	Sweden	6 7	Retrospective cohort	33	375 mg/m <sup>2</sup> /w x 4 w	22 m‡	LN duration Baseline serum creatinine Baseline proteinuria Baseline Anti-dsDNA Baseline detectable B cell	Renal response	Not indicated
Marquez et al. [36]#	Spain	5	Prospective cohort	84	375 mg/m <sup>2</sup> /week x 4 or 1000 mg x 2	6 m	Genetic factors	Clinical Complete response	Socio-demographic and concomitant therapies
Ng et al. [33] ¥	UK	7	Retrospective cohort	32	1 g of rituximab x 2 plus 500-750 mg IVC	39 m‡	Anti-ENA	Clinical flare	Performed but unknown confounders
Robledo et al. [34] #	Spain	5	Prospective cohort	81	375 mg/m <sup>2</sup> /week x 4 or 1000 mg x 2	6 m	Genetic factors	Clinical response	Not indicated
Robledo et al. [35] #	Spain	5	Prospective cohort	83	375 mg/m <sup>2</sup> /week x 4 or 1000 mg x 2	6 m	Genetic factors	Clinical response	Not indicated
Vital et al. [13] &	UK	7	Prospective cohort	39	1000 mg x 2	6 m	Anti-ENA B cell depletion B cell repopulation	Clinical response Clinical relapse	Not indicated

Vital et al. [37] &	UK	6 7	Retrospective cohort	82	1000 mg × 2	6 m	Cutaneous phenotype Autoantibodies Complement B cell depletion	Mucocutaneous response Cutaneous flare	Not indicated
---------------------	----	--------	----------------------	----	-------------	-----	---	---	---------------

Studies are listed in alphabetical order; †mean, ‡median; ¥, # and & multiple papers on partially the same cohort. Anti-ENA: anti-extractable nuclear antigen; BAFF, B-cell-activating factor; HCQ: hydroxychloroquine; m, months; IVC, intravenous cyclophosphamide; LN, lupus nephritis; MLN, membranous lupus nephritis; PICO, Population, Intervention, Comparator, Outcome (number of PICO question); RCT, randomized clinical trial; SELENA-SLEDAI: Safety of Estrogens in Lupus Erythematosus National Assessment-SLE disease activity index; UK, United Kingdom; w, weeks; y, years

### 3.3 Characteristics of possible predictive or prognostic factors and outcomes to RTX

Predictive or prognostic factors were grouped into six categories: sociodemographic, genetic, disease related, and laboratory biomarkers. Outcomes were evaluated as follows: global, renal or cutaneous response/remission were evaluated by 12 studies [8;9;13;27;28;30-32;34-37]; global, renal or cutaneous relapse/flare were reported in 5 studies [26;27;29;33;37]; harms including adverse events were evaluated by 2 studies [13;31] and changes in biomarkers were reported in 4 studies [9;13;25;26].

### 3.4 Methodological quality of included studies

#### 3.4.1 Risk of bias in RCTs

Risk of bias assessment was based on the main results paper of the included RCTs. The methods of randomisation and allocation concealment were unclear (high risk) in both RCTs. Two trials were described as double blinded (participant and outcome assessment) and rated

as low risk of performance and detection bias [8;9]. These trials included an intention to treat (ITT) analysis, had no evidence of selective outcome reporting and dropout rate analyses were adequately presented (low risk of attrition bias). The RCTs either declared sponsorship by a pharmaceutical industry company, or included an author who declared pharmaceutical company affiliation; these were judge as carrying high risk bias related to the funding source (Figure 2).

**Figure 2** Risk of bias summary of RCTs included

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Merrill 2010	?	?	+	+	+	+	?
Rovin 2012	?	?	+	+	+	+	?



### **3.4.2 Quality of subgroups (moderation) analysis**

At least nine subgroup analyses were conducted in one RCT [8], without providing a clear rationale a priori for most of them. None of the sub-group analyses provided confirmatory evidence with one analysis providing exploratory evidence only (Supplementary file B, Table B.1).

### **3.4.3 Risk of bias in prognostic factor studies based on observational cohorts**

The overall methodological quality of six studies scored 'moderate', seven studies scored 'low', and no study was judged as 'high' quality (Supplementary file B, Table B.2). Due to lack of reporting on key characteristics of the source population ('study participation') and of participants loss to follow-up ('study attrition'), bias could not be ruled out, therefore studies were classified as 'moderate' (n = 4) or 'high' risk (n = 9) of selection bias. In 10 studies, measurement of prognostic factors and outcomes were performed in a similar, valid, and reliable way for all participants ('low' to 'moderate' risk of bias), although, in three studies outcomes measurements were based on clinical judgment instead of valid criteria [34-36], resulting in high risk of bias for these domains. The statistical analysis, model-building process or completeness of reporting was judged to be inadequate in all studies ('moderate' to 'high' risk of bias). In particular, there was insufficient description of how factors were selected for inclusion in the multivariable analysis (Supplementary file D, Table D.1-D.7).

## **3.5 Synthesis of evidence**

### **3.5.1 Sociodemographic factors (PICO 1 and 4)**

#### **3.5.1.1 Age, gender and race**

One RCT [8] found no association between age or gender and response to RTX. In a pre-specified secondary analysis being of African American/Hispanic race/ethnicity showed a

larger effect of RTX on no clinical response at week 52 compared to those of other ethnic origin. No differences were seen for secondary endpoints such as quality of life or major clinical response with a prednisone dosage of < 10 mg/day in the same subgroup (low QoE, Supplementary file C).

### 3.5.2 Genetic factors (PICO 5)

In one cohort study [36], both IL2/IL21 (rs6822844) GG genotype and G allele were significantly associated with clinical response when adjusted for age, gender and concomitant therapies (OR = 6.43 95% CI 1.42–21.07) (Table 3). The QoE for this association was downgraded to low due to the early phase of investigation designed to generate hypotheses and imprecision of the results but also upgraded given the strength of the association (Supplementary file D, Table D.1).

Two other genetic variants -174 IL6 (rs1800795) and Fc gamma-receptor III a (FCGR3A) 158F/V were evaluated in a single cohort study each and were not related to clinical response [34;35] (Table 3).

**Table 3** Summary of evidence for factors associated with global clinical response

Factor identified	Study	N	Outcome	Unadjusted ES (95% CI)/univariable analysis	P value	Adjusted ES (95% CI)	P value	Overall quality
- 174 IL-6 (rs1800795) SNP GG vs GC genotype	Robledo et al. [34]	40/36	Complete or partial response	36 (90.0%) vs 32 (88.9%) RR=1.01 (0.87-1.18)	0.87	NP	NP	+
- 174 IL-6 (rs1800795) SNP GG vs CC genotype	Robledo et al. [34]	40/8	Complete or partial response	36 (90.0%) vs 5 (62.5%) RR=1.26 (0.77-2.03)	0.34	NP	NP	+
- 174 IL-6 (rs1800795) SNP GC vs CC genotype	Robledo et al. [34]	36/8	Complete or partial response	32 (88.9%) vs 5 (62.5%) RR=1.42 (0.82-2.46)	0.21	NP	NP	+
FCGR3A-158 SNP VV vs FF genotype	Robledo et al. [35]	13/4	Complete or partial response	12 (92.3%) vs 36 (81.8%) RR=1.13 (0.91-1.39)	0.25	NP	NP	+
FCGR3A-158 SNP FV vs VV genotype	Robledo et al. [35]	24/13	Complete or partial response	23 (95.8%) vs 12 (92.3%) RR=1.04 (0.87 to 1.24)	0.68	NP	NP	+
FCGR3A-158 SNP FV vs FF genotype	Robledo et al. [35]	24/4	Complete or partial response	23 (95.8%) vs 36 (81.8%) RR=1.17 (0.99-1.37)	0.056	NP	NP	+

Genetic

	IL2/IL21 SNP (rs6822844) GG vs GT genotype	Marquez et al. [36]	66/18	Complete or partial response	61 (92.4%) vs 12 (66.7%); RR = 1.39 (0.99–1.94)	0.055	<b>OR = 6.43 (1.42–21.07)</b>	0.016	++
Disease-related	Baseline SLEDAI	Fernandez-Nebro et al. [31]	116	Complete or partial remission	OR= 1.1 (1.03-1.2)	0.001	<b>OR= 1.1, (1.04-1.16)</b>	0.001	+
	Previous discoid rash	Fernandez-Nebro et al. [31]	116	Complete or partial remission	<b>OR= 4.4 (1.2-15.8)</b>	0.025	NS	0.08	+
	Previous severe hematologic disorder	Fernandez-Nebro et al. [31]	116	Complete or partial remission	<b>OR= 0.3 (0.1-0.7)</b>	0.003	<b>OR= 0.17 (0.06-0.46)</b>	<0.001	+
	Previous treatment with immunoglobulins	Fernandez-Nebro et al. [31]	113	Complete or partial remission	<b>OR= 0.3 (0.3-0.7)</b>	0.007	NS	0.13	+
	Previous treatment with prednisolone $\geq 100$ mg/day	Fernandez-Nebro et al. [31]	116	Complete or partial remission	OR= 1.3 (1.1-15.0)	0.032	<b>OR= 7.3 (1.6-32.9)</b>	0.010	+
Laboratory biomarker	BCD <12 vs $\geq 12$ months	Dias et al. [30]	34/64	BILAG score at 6 months	8.78 vs 5.89	0.004	NP	NP	+
				BILAG score at 12 months	7.64 vs 5.29	0.017	NP	NP	+

Complete vs. incomplete BCD	Vital et al. [13]	16/21	Major or partial clinical response	<b>16 (100%) vs 14 (66.7%)</b> <b>RR = 1.5 (1.10-2.02)</b>	<b>0.00</b> <b>8</b>	NP	NP	+
-----------------------------	-------------------	-------	------------------------------------	---	-------------------------	----	----	---

Abbreviation: BCD: B cells depletion; ES: effect size; CI: confidence interval; NP, information not presented, NS: not significant; RR: relative risk; SLEDAI: systemic lupus erythematosus disease activity.

For overall quality of evidence: +, very low; ++, low; +++, moderate; +++++, high

### 3.5.3 Disease-related factors (PICO 2 and 6)

#### 3.5.3.1 Disease phenotype

BILAG-defined mucocutaneous or musculoskeletal system involvement, were also assessed as pre-specified subgroups analysis in the EXPLORER trial with no difference in effect estimates found between both interventions groups [8]. The QoE of this RCT was downgraded due to these being subgroup analyses with no tests for interaction and providing exploratory evidence only.

Similarly, the prognostic value of skin phenotype on response and future flare in two cohort studies was unclear with both assessed as having high risk of bias [31;37] (Table 3, 5 and 6). In a single cohort study, those with previous serious haematologic disorder were 83% less likely to achieve a beneficial response [31] (very low QoE).

A single (very low QoE) cohort study also found that membranous and proliferative LN had similar renal responses following B-cell depleting (BCD) therapy [32] (Table 7).

### 3.5.3.2 Disease severity

A single RCT found that baseline BILAG A score did not predict a differential clinical response to RTX compared to control at week 52 [8]. In contrast, high baseline SLEDAI score was associated with better RTX global response at 6 months in one cohort study with high risk of bias [31] (Table 3).

A longer duration (median 19 months) of lupus nephritis (LN) was associated with a lower likelihood of renal response in one cohort with serious limitations [28]. The age adjusted Charlson comorbidity index and the number of severely affected organ systems were associated with more severe adverse events and more severe infections with RTX therapy in one cohort study (very low QoE) (Table 8) [31].

**Table 4** Summary of evidence for factors associated with overall clinical relapse or flare

Factor identified	Study	N	Outcome	Unadjusted ES (95% CI)/univariable analysis	P value	Adjusted ES (95% CI)	P value	Overall quality	
Laboratory biomarkers	Baseline high (>100 IU/ml) vs low or normal anti-dsDNA antibodies	Lazarus et al. [27]	26/35	Early relapse	NP	NS	NP	NP	+
	Baseline presence vs absence of anti-dsDNA	Catapano et al. [29]	14/17	Time of relapse	NP	NS	NP	NP	+
	Baseline presence of anti-ENA antibodies vs lack of anti-ENA	Ng et al. [33]	21/7	Flare	NP	0.007	<b>OR = 8.0 (1.2-55)</b>	0.034	+
		Vital et al. [13]	39	Early relapse	NP	Sig	NP	NP	+
	Baseline BAFF levels	Catapano et al. [29]	10/21	Time of relapse	NP	NS	NP	NP	+
		Carter et al. [26]	35	Relapse	NP	>0.55	NP	NP	+
	B cell repopulation: higher number of memory cell	Vital et al. [13]	32	Early relapse	NP	0.02	NP	NP	+
	B cell repopulation: number of plasmablast cell	Vital et al. [13]	32	Early relapse	80% vs 0%	< 0.001	NP	NP	+
				Late relapse	100% vs 27%	NP	NP	NP	+

>0.0008 x 10 <sup>9</sup> /liter vs <0.0008 x 10 <sup>9</sup> /liter								
B cell repopulation with higher (>100 IU/ml) vs lower anti- DNA antibodies levels	Lazarus et al. [27]	17/2 0	Early relapse	NP	0.02	NP	NP	+

Abbreviations: anti-ENA: anti-extractable nuclear antigen; BAFF: B-cell-activating factor; BCD: B cell depletion; ES: effect size; CI: confidence interval; NP, information not presented, NS: not significant; OR: odds ratio; Sig: significant.

For overall quality of evidence: +, very low; ++, low; +++, moderate; +++++, high

Accepted manuscript



**Table 5** Summary of evidence for factors associated with cutaneous response

Factor identified	Study	N	Cutaneous Outcome	Unadjusted ES (95% CI)/univariate analysis	P value	Adjusted ES (95% CI)	P value	Overall quality	
Disease related	Subtype skin disease: ACLE vs CCLE	Vital et al. [37]	14/8	Response	6 (42.9%) vs 0 (0.0%)  RR = 7.8 (0.49-122.65)	0.14	NP	NP	+
Laboratory biomarker	Baseline positive vs. negative anti-Ro/SSA antibodies	Vital et al. [37]	16/10	Response	<b>3 (18.8%) vs 6 (60.0%)</b>  <b>RR = 0.31 (0.10- 0.97)</b>	0.04	NP	NP	+
	Baseline positive vs negative anti-La/SSB antibodies	Vital et al. [37]	8/18	Response	2 (25.0%) vs 7 (38.9%)  RR = 0.64 (0.17-2.43)	0.65	NP	NP	+
	Baseline positive vs negative anti-dsDNA antibodies	Vital et al. [37]	14/8	Response	7 (50.0%) vs 2 (16.7%)  RR = 3.0 (0.82-5.17)	0.11	NP	NP	+
	Baseline positive vs negative anti-Sm antibodies	Vital et al. [37]	4/22	Response	1 (25.0%) vs 8 (36.4%)  RR = 0.68 (0.62-2.17)	0.68	NP	NP	+

Baseline positive vs negative anti-RNP antibodies	Vital et al. [37]	7/19	Response	0 (0.0%) vs 7 (47.4%) RR = 0.13 (0.008-2.0)	0.14	NP	NP	+
Low vs normal C3	Vital et al. [37]	9/17	Response	3 (33.3%) vs 6 (35.3%) RR = 0.94 (0.30-2.91)	0.09	NP	NP	+
Low vs normal C4	Vital et al. [37]	11/16	Response	4 (36.4%) vs 5 (31.3%) RR = 1.16 (0.40-3.38)	0.78	NP	NP	+
Complete (0.0001 x 10 <sup>9</sup> cells/liter) vs incomplete BCD	Vital et al. [37]	10/16	Response	4 (40.0%) vs 5 (31.3%) RR = 1.28 (0.44-3.66)	0.64	NP	NP	+

ACLE: acute cutaneous lupus erythematosus; BCD: B cells depletion; CLE: chronic cutaneous lupus erythematosus; ES: effect size; NP, information not presented, NS: not significant; SCLE: subacute cutaneous lupus erythematosus; SLEDAI: systemic lupus erythematosus disease activity.

For overall quality of evidence: +, very low; ++, low; +++, moderate; +++++, high

**Table 6** Summary of evidence for factors associated with cutaneous relapses

Factor identified	Study	N	Cutaneous Outcome	Unadjusted ES (95% CI)/ univariable analysis	P value	Adjusted ES (95% CI)	P value	Overall quality	
Disease related	Subtype skin disease: ACLE vs CCLE	Vital et al. [37]	14/8	Relapse	6 (42.9%) vs 0 (0.0%) RR = 7.8 (0.49-122.65)	0.14	NP	NP	+
	Baseline anti-Ro/SSA antibodies positive vs negative	Vital et al. [37]	17/15	Relapse	8 (47.1%) vs 5 (33.3%) RR = 1.41 (0.58 to 3.38)	0.44	NP	NP	+
Laboratory biomarker	Baseline positive vs negative anti-La/SSB antibodies	Vital et al. [37]	9/23	Relapse	4 (44.4%) vs 8 (34.8%) RR = 1.28 (0.51 to 3.20)	0.60	NP	NP	+
	Baseline positive vs negative anti-dsDNA antibodies	Vital et al. [37]	17/15	Relapse	7 (41.2%) vs 5 (33.3%) RR = 1.24 (0.49 to 3.08)	0.65	NP	NP	+
	Baseline positive vs negative anti-Sm antibodies	Vital et al. [37]	4/28	Relapse	0 (0.0%) vs 12 (42.9%) RR = 0.23 (0.01-3.32)	1.07	NP	NP	+
	Baseline positive vs negative anti-RNP antibodies	Vital et al. [37]	7/25	Relapse	4 (57.1%) vs 8 (32.0%) RR = 1.78 (0.75- 4.21)	0.18	NP	NP	+

Low vs normal C3	Vital et al. [37]	12/20	Relapse	6 (50.0%) vs 6 (30.0%)  RR = 1.66 (0.69-4.00)	0.25	NP	NP	+
Low vs normal C4	Vital et al. [37]	14/18	Relapse	6 (42.9%) vs 6 (33.3%)  RR = 1.29 (0.53-3.13)	0.58	NP	NP	+
Complete (0.0001 x 10 <sup>9</sup> ) cells/liter vs incomplete BCD	Vital et al. [37]	12/20	Relapse	3 (25.0%) vs 9 (45.0%)  RR = 0.56 (0.19-1.66)	0.29	NP	NP	+

ACLE: acute cutaneous lupus erythematosus; BCD: B cells depletion; CCLE: chronic cutaneous lupus erythematosus; ES: effect size; NP, information not presented, NS: not significant; SCLE: subacute cutaneous lupus erythematosus; SLEDAI: systemic lupus erythematosus disease activity.

For overall quality of evidence: +, very low; ++, low; +++, moderate; +++++, high

**Table 7** Summary of evidence for factors associated with renal response

Factor identified	Study	N	Renal Outcome	Unadjusted ES (95% CI)/univariable analysis	P value	Adjusted ES (95% CI)	P value	Overall quality	
Disease related	Duration of lupus nephritis, months	Lindholm et al. [28]	11/6	Complete/partial response vs. no response	9 vs 19	NS	NP	NP	+
	MLN class vs PLN class	Jónsdóttir et al. [32]	15/28	Increase serum albumin	NP	NS	NP	NP	+
				Mean serum creatinine levels improved	Only in MLN	NP	NP	NP	+
				Reduction in proteinuria	NP	NS	NP	NP	+
				Improvement in C3	NP	NS	NP	NP	+
Reduction in anti-dsDNA	Only in PLN	<0.02	NP	NP	+				
Laboratory biomarker	Baseline serum creatinine, $\mu$ moles/l	Lindholm et al. [28]	11/6	Complete/partial response vs. no response	$86.1 \pm 30.9$ vs $207.2 \pm 86.6$	0.006	NP	NP	+
	Baseline eGFR $\geq 30$ vs $< 30$ ml/min	Lindholm et al. [28]	13/4	Complete/partial response	11 (84.6%) vs 0 (0.0%) RR = 8.21 (0.58 - 115.21)	0.58	NP	NP	+
	Baseline proteinuria, g/24 h	Lindholm et al. [28]	11/6	Complete/partial response vs. no response	$3.4 \pm 2.1$ vs $5.0 \pm 1.6$	NS	NP	NP	+
	Baseline anti-	Lindholm et al. [28]	11/6	Complete/partial response	$38 \pm 4.9$ vs	NS	NP	NP	+

dsDNA antibodies, U/ml	m et al. [28]		vs. no response	37.5 ± 8.0				
Baseline complement C3, g/l	Lindhölm et al. [28]	11/6	Complete/partial response vs. no response	1.0 ± 0.1 vs 1.1 ± 0.3	NS	NP	NP	+
Baseline detectable CD 19+ lymphocyte	Lindhölm et al. [28]	11/6	Complete/partial response vs. no response	9 (81.8%) vs 2 (33.3%) RR = 2.45 (0.76-7.87)	NS	NP	NP	+

BCD: B cells depletion; CCLE: chronic cutaneous lupus erythematosus; eGFR: estimated glomerular filtration rate; ES: effect size; HCQ: hydroxychloroquine; MLN: membranous lupus nephritis; NP: information not presented, NS: not significant; PLN: proliferative lupus nephritis.

For overall quality of evidence: +, very low; ++, low; +++, moderate; +++++, high

**Table 8** Summary of evidence for factors associated with side effects

Factor identified	Study	N	Overall Outcome	Unadjusted ES (95% CI)/univariable analysis	P value	Adjusted ES (95% CI)	P value	Overall quality	
Disease-related	Comorbidity*	Fernandez-Nebro et al. [31]	125	Adverse events	HR = 1.6 (1.1–2.4)	0.030	HR = 1.6 (1.0–2.6)	0.049	+
	No. of severely involved organ systems (per organ involved)	Fernandez-Nebro et al.[31]	125	Adverse events	<b>HR = 2.0 (1.4–2.9)</b>	<0.001	<b>HR = 2.0 (1.3–2.9)</b>	0.001	++
	Previous treatment with steroid bolus (Yes/No)	Fernandez-Nebro et al. [31]	125	Adverse events	<b>HR = 5.4 (2.0–14.8)</b>	0.001	<b>HR = 5.9 (1.9–18.4)</b>	0.002	++
Laboratory biomarker	Baseline high leukocyte count, $\times 10^9/L$	Fernandez-Nebro et al. [31]	125	Adverse events	HR = 1.2 (1.0–1.3)	0.045	<b>HR = 1.2 (1.0–1.4)</b>	0.046	+
	Complete BCD depletion vs incomplete BCD cell depletion	Vital et al. [13]	16/21	Hospital admissions	4 (25%) vs 10 (47.6%) RR = 0.54 (0.20-1.37)	NP	NP	NP	+

ES: effect size; HR: hazard ratio; NP, information not presented, NS: not significant; SLEDAI: systemic lupus erythematosus disease activity; TC: total cholesterol; TG: triglycerides. \*Age-adjusted Charlson comorbidity index

For overall quality of evidence: +, very low; ++, low; +++, moderate; +++++, high

The role of previous treatments, a potential proxy of more severe disease or a different

phenotype, has been evaluated in only two studies (one RCT and one cohort study). In the

EXPLORER trial a post-hoc analysis of patients in previous treatment with methotrexate found a greater fall in mean BILAG global scores in RTX vs placebo treated patients. There was however no difference in achievement of the primary endpoint (low QoE) [8]. Previous treatment with prednisone > 100 mg/day was related to better clinical response (very low QoE) and previous treatment with steroid bolus was associated with more adverse events (low QoE) in one cohort study. It was unclear what other factors were adjusted for in this cohort [31]. A univariable analysis in the same cohort also showed that previous treatment with immunoglobulins was associated with a reduced likelihood of clinical response; an association not confirmed in a multivariate analysis [31] (Table 3).

### **3.5.4 Laboratory biomarker values (PICO 3 and 7)**

#### **3.5.4.1 Baseline laboratory biomarkers**

In a post-hoc subgroup analysis from the EXPLORER Trial that used normalisation of serology as an end-point, patients with positive dsDNA (> 30 UI/ml) who lacked RNA-binding protein (RBP-) had reduced anti-dsDNA antibodies after RTX treatment compared to placebo-treated patients. In contrast, patients with both dsDNA and RBP (> 120 AU/ml) antibodies had a similar reduction in anti-dsDNA antibodies in both treatment arms [25]. This study also found that repopulation of CD19+ B cells in dsDNA+RBP+ and dsDNA+RBP- patients were similar despite differences in anti-dsDNA antibodies levels (Table 9). The QoE of this RCT was downgraded due to unclear allocation concealment and post hoc subgroup analysis with insufficient evidence.

Patients with baseline renal impairment (high serum creatinine levels and a GFR < 30 ml/min) were less likely to have a renal response whilst a higher baseline proteinuria was not associated with renal responses in one cohort study. Analyses were not adjusted for potential



confounding [28] (Table 7). Baseline high leukocyte count was found to be related to an increased risk of severe infections during RTX in one cohort study [31] (very low QoE) (Table 8).

A number of studies assessed baseline levels of biomarkers including anti-double stranded DNA (anti-dsDNA) antibodies, low C3 and/or C4 complement, serum B-cell-activating factor (BAFF) and baseline CD19 counts. These studies were rated as low QoE and did not find any of these to be predictors of treatment outcome. Whilst 4 cohort studies assessed anti-DNA against a range of global and organ specific response measures, these other baseline biomarkers have only been assessed in one or two studies each.

Univariable analysis from two cohorts [33] found an association between anti-extractable nuclear antigen antibody (anti-ENA) and flares, but another cohort failed to find this association and only one study confirmed this in a multivariable analysis [33]. Evidence from these studies was downgraded because of inconsistency and high risk of bias.

Regarding specific anti-ENA antibody specificities, anti-Ro was associated with poorer mucocutaneous responses but not with mucocutaneous flares in univariable analysis from one small cohort [37] (n = 26) very low QoE) (Table 5 and 6).

**Table 9** Summary of evidence for factors associated with changes in biomarkers

Factor identified	Study	N	Overall Outcome	Unadjusted ES (95% CI)/univariable analysis	P value	Adjusted ES (95% CI)	P value	Overall quality
Baseline high anti-dsDNA (>123/ml)	Rovinet al. [9]	72	B cell depletion	NP	Sig	NP	NP	+
Baseline anti-dsDNA titers	Vital et al. [13]	37	Incomplete B cell depletion	NP	NS	NP	NP	+
Baseline anti-dsDNA <sup>+</sup> RN P <sup>-</sup> vs anti-dsDNA <sup>+</sup> RN P <sup>+</sup>	Tew et al. [25]	97/68	Decreased anti-dsDNA	NP	<0.025	NP	NP	+
			Increased complement	NP	NS	NP	NP	+
Baseline anti-ENA presence	Vital et al. [13]	37	Incomplete B cell depletion	NP	NS	NP	NP	+
Baseline low C3 or C4 levels	Vital et al. [13]	37	Incomplete B cell depletion	NP	NS	NP	NP	+
Baseline median levels of memory, cells/liter	Vital et al. [13]	37	Complete depletion vs. persistent B cells	0.0065 x 10 <sup>9</sup> vs 0.0157 x 10 <sup>9</sup>	0.049	NP	NP	+
Baseline median levels of plasmablast, cells/liter	Vital et al. [13]	37	Complete depletion vs. persistent B cells	0.0015 x 10 <sup>9</sup> vs 0.0037 x 10 <sup>9</sup>	0.030	NP	NP	+
Baseline high vs low	Tew et al.	16/9	Changes in anti-	NP	Sig	NP	NP	+

Laboratory biomarker values

BAFF	[25]		dsDNA and compleme nt					
Baseline BAFF levels, ng/ml	Carte r et al. [26]	34	Time to peripheral B cell repopulati on < 26 weeks vs > 26 weeks	1.12 ± 0.20 vs 1.52 ± 0.38	> 0.05	NP	NP	+
Baseline positive vs negative IFN signature	Tew et al. [25]	16/9	Changes in anti- dsDNA and compleme nt	NP	NS	NP	NP	+

BAFF: ES: effect size; HR: hazard ratio; NP, information not presented, NS: not significant; Sig: significant; SLEDAI: systemic lupus erythematosus disease activity; TC: total cholesterol; TGs: triglycerides.

For overall quality of evidence: +, very low; ++, low; +++, moderate; +++++, high

#### 3.5.4.2 Pharmacodynamic biomarkers post-RTX

Two cohorts assessed the association between degree of BCD and clinical response (one on global response and one for mucocutaneous response). One cohort study (n = 37) found that all patients with complete B cell depletion at 6 weeks (n= 16) had higher major or partial global clinical responses at 26 weeks, and all non-responders had persistent B cells after RTX therapy (n=14) [13]. No association between the degree of initial B cell depletion and response was observed for cutaneous disease (n = 26) [37] (Tables 3 and 4), and no association was found when using relapse as the outcome in this subgroup.

One cohort study examined whether BCD could have a relationship with harm during RTX therapy (rates of hospitalization). There was no adverse influence on safety in patients with complete BCD or prolonged suppression of memory and plasma cell numbers [13] (Table 8).

The duration of BCD was evaluated in one cohort study (n = 98), with longer duration ( $\geq 12$  months) of depletion being associated with a better outcome at 6 and 12 months. Similarly, lymphopenia at any time during the course of the patient's disease course was also associated with a better outcome (longer duration of depletion) [30] (Table 3). The quality of evidence for the association of the degree or duration of BCD with treatment outcomes or harm was graded as very low given imprecision of estimates and limitations of study design.

With regard to peripheral B cell repopulation, memory and plasmablast cells repopulation at 26 weeks was significantly associated with earlier relapse and there were also significantly higher numbers of memory and plasmablast cells ( $\geq 0.0008 \times 10^9/\text{liter}$ ) in patients with earlier relapse in one cohort study (very low QoE) (Table 4).

In another cohort (very low QoE), higher B-cell numbers could be observed as early as 8 weeks post-RTX in those with early (before 18 months) relapse. Also, in this study early relapse was associated with lower levels of repopulation in patients with high ( $> 100 \text{ UI/ml}$ ) [27] (Table 4).

#### 4. DISCUSSION

This systematic review aimed to identify potential predictors of differential treatment effect (moderators) in RCTs and prognostic factors from cohort studies for outcomes of RTX therapy for SLE. Using validated tools, the overall quality of most of the investigated predictive or prognostic factors was low or very low, which means that our confidence in the majority of these is very limited. The quality of evidence was affected mainly by limitations associated with: (1) the evidence arising generally from explanatory studies conducted in an early, hypothesis-generating phase of investigation; (2) risk of publication bias (or small study) due to associations of prognostic factors with outcome mainly reported by a very small

number of studies with small sample size; (3) several included studies only reported “p” values rather than effect sizes which limits conclusions to be drawn about the precision of effect estimates and clinical relevance of the study findings; (4) results derived from subgroup analyses without interaction tests in only a small number of studies, (5) many associations explored in only one study and (6) several studies reported from the same centre or cohort, which makes evaluating consistency of results across studies difficult. Even when assessing a common marker such as anti-ENA antibodies and B-cell dynamics post-RTX different definitions and cut-points between studies limit the ability to validate or confirm findings. Further primary hypothesis-driven research based on longitudinal studies of sufficient sample size exploring factors associated with RTX outcomes in SLE patients is therefore needed to confirm and validate which, if any of these, factors truly predict outcomes of RTX therapy.

A number of factors associated with clinical response to rituximab are suggested by this review that will require further study. In a pre-specified secondary analysis of the EXPLORER trial, African American/Hispanic patients who received RTX were more likely to achieve the primary endpoint compared to the same race/ethnicity groups receiving standard of care (control arm). This difference was however driven by a lower response to standard of care in African American/Hispanic patients compared to overall trial population [8]. It therefore remains to be seen whether this simply represents overall less stable disease in this subgroup or whether RTX has indeed a differential effect in these race/ethnicity subgroups. Similarly in the same trial, RTX treated patients receiving co-therapy with MTX achieved a lower global BILAG score by 52 weeks compared to placebo treated patients, however the primary endpoint of the trial did not differ according to co-therapy. Whether this

represents a particular synergy between RTX and MTX in SLE patients or not, cannot be deduced from this data.

In the cohort studies, the majority of prognostic factors were limited to small early phase studies and often a single study examining each factor. Several factors including anti-dsDNA status were examined across a number of cohorts [27-29;37] and did not show any association with RTX responses (either clinical or serological changes). Any conclusions are again limited since most cohorts were small and used different outcomes measures and also there have been a number of cohorts from which multiple publications have arisen and it is unclear the degree of overlap in the patients studied. We therefore cannot confidently exclude such a factor as being of importance.

A number of factors suggested in at least one study included IL2/IL21 SNP GG genotype and G allele which were associated with global clinical response in one cohort study [36]. Whilst this needs confirmation in a much larger cohort, attention also needs to be paid to whether it is a predictor of response only for RTX or whether it simply predicts a better response to other immune-modulatory therapy as well. This will be important to determine the true significance of such a predictive biomarker. Of interest in a recent systematic review of predictors of response to biologic therapy in RA, conflicting results were reported for FCGR variants and no association between RTX responses and IL6 promoter 174 were observed [38]. In SLE these variants also did not show any association with global SLE responses to RTX.

Two single-centre cohort studies found that the level of B cell depletion achieved as well as the early return of B cell (especially plasmablasts and memory B cells) were associated with early relapses in studies from two cohorts [13;27]. Such factors are of interest as the latter pattern of B-cell depletion and return are likely to be specific to the action of RTX and

therefore will act as a pharmacodynamic measure of RTX efficacy and future relapses. At a pragmatic and clinical level, more complex monitoring than simply assessing baseline factors may therefore be needed to fully understand the specificity of responses to RTX and to plan more tailored therapy. Such dynamic markers of course have the limitation of not allowing clinicians to decide *a priori* whether to treat or not treat with RTX but will be of great value in planning future courses and potentially helping to make an early declaration of therapeutic ‘failure’ so that other therapies can be initiated sooner. For such factors to be validated to the degree of certainty required to formalise therapeutic decisions will however require large multicentre, quality assured confirmatory studies. Such studies do also provide potentially important insights into the mechanisms of action of RTX in mediating prolonged responses in some patients. Recent work on regulatory B cells suggests that it is likely to be the pattern of return of B-cell subsets rather than total B-cell numbers that determine future relapses, providing a potential explanation for the inconsistencies in the value of B cell markers in determining response in the cohorts reviewed [39].

We noted that there are differences across studies in how specific organ systems responded to RTX therapy. For example, one small study suggested that Ro+ve patients and those with chronic cutaneous lupus had poorer responses [37]. In addition patients with elevated creatinine and those with longer duration of LN responded less well in one cohort study [28]. Whether these observations relate to more scarring/fibrosis and hence a lower likelihood of response in these subsets or whether they point to a different pathogenesis (e.g. T-cell or IFN-driven disease) will require further study. All these studies were however rated as low or very low QoE and therefore confirmation of these observations are necessary in parallel with a better understanding of the explanations for any such lack of response to RTX.

Factors related with drug administration such as concomitant therapy, administration schedules or human antichimeric antibodies (HACA) were not included in our analysis as

such studies are more focused on optimal delivery of the treatment, rather than investigating which patient or disease characteristics (prognostic factors) are associated with positive outcomes of treatment.

The strength of this review lies in the fact that this is the first comprehensive review that provides a summary of the possible predictive or prognostic factors in SLE patients with RTX therapy. However, we recognise several limitations to the review. First, due to the small number of studies included and the heterogeneity between studies we were not able to combine the results of studies from a quantitative perspective. We have also synthesized the evidence on associations between a single potential prognostic factor and an outcome variable when the study employed either univariable analyses or multivariable analyses. By including both types of analyses we may have introduced a degree of heterogeneity. One major limitation is that even in these best case scenarios, the variables controlled for in each analysis may differ between studies and we therefore cannot assume that any of the single identified associations would remain if more consistent modelling was applied in all studies. Second, most studies included in this systematic review were in SLE patients who failed to respond to conventional treatment, therefore, we cannot extrapolate our results to patients with newly diagnosed SLE, who are candidate for standard therapy. A few small studies have assessed the effectiveness of rituximab in those patients [40;41], however, some of these studies were not included in our review due to mainly either no prognostic factor analysis was provided or less than 30 patients were included (Supplementary file A, Table A.7). Third, It is also possible that we have missed studies that are not indexed in these databases, but by checking references of included studies, we made every effort to identify all relevant articles. Finally, no attempt was made to contact authors to obtain individual patient-level data or carry out a comprehensive meta-analysis.



Clinical experience, observational studies and several international guidelines [10;11] support the use of RTX for the treatment of refractory SLE as well as disease with sustained activity that persists despite conventional immunosuppression therapy. Despite of more widespread use and studies supporting its efficacy, we found limited evidence to predict which patient groups will respond better (or worse) to RTX to permit a stratified approach to the use of this agent. A number of demographic, serological, genetic and pharmacodynamic markers were identified in this review, however most studies addressing these prognostic factors were hypothesis-generating and therefore cannot be used to make any specific recommendations for routine clinical practice. It is therefore important to validate any predictive or prognostic factors in hypothesis-testing studies and determine whether such markers are associated with SLE outcomes in general or whether they are specific for RTX therapy. Such an approach will pave the way for more personalised use of this agent in the future.

## **5. Acknowledgements**

Dr Pirone is supported by a Società Italiana di Reumatologia / British Society for Rheumatology travel scholarship

Dr Mendoza Pinto is an Associated Research at the Mexican Institute for Social Security and received support from Conacyt for this research.

Prof van der Windt is a member of PROGRESS; Medical Research Council Prognosis Research Strategy (PROGRESS) Partnership (G0902393/99558)

Dr Parker is supported by the National Institute for Health Research Manchester Biomedical Research Unit and the NIHR/Wellcome Trust Manchester Clinical Research Facility.

Prof Bruce is an NIHR Senior Investigator and is funded by Arthritis Research UK, the Medical Research Council, the National Institute for Health Research Manchester Biomedical Research Unit and the NIHR/Wellcome Trust Manchester Clinical Research Facility. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. Prof Bruce also acknowledges research grants from UCB, GSK, Roche and Genzyme-Sanofi.

We would like to acknowledge the input of Mary Ingram, Medical Librarian, The University of Manchester, with the literature search and strategy.

## 6. Source funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

## 7. REFERENCE

- [1] Hamburg MA, Collins FS. The path to personalized medicine. *N Engl J Med* 2010 Jul 22;363:301-4.
- [2] Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. *Nat Rev Drug Discov* 2007;6:287-93.
- [3] Rothwell PM, Mehta Z, Howard SC, Gutnikov SA, Warlow CP. Treating individuals 3: from subgroups to individuals: general principles and the example of carotid endarterectomy. *Lancet* 2005;365:256-65.
- [4] Tsokos GC. Systemic lupus erythematosus. *N Engl J Med* 2011;365:2110-21.

- [5] Cambridge G, Perry HC, Nogueira L, Serre G, Parsons HM, De La Torre I, et al. The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment. *J Autoimmun* 2014 May;50:67-76.
- [6] Furtado J, Isenberg DA. B cell elimination in systemic lupus erythematosus. *Clin Immunol* 2013 Feb;146(2):90-103.
- [7] Duxbury B, Combescure C, Chizzolini C. Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. *Lupus* 2013 Dec;22(14):1489-503.
- [8] Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. *Arthritis Rheum* 2010 Jan;62(1):222-33.
- [9] Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. *Arthritis Rheum* 2012 Apr;64(4):1215-26.
- [10] Hahn BH, McMahon MA, Wilkinson AE. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. *Arthritis Care Res (Hoboken)* 2012;64:797-808.
- [11] Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. *Ann Rheum Dis* 2012;71:1771-82.
- [12] Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D, et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythematosus. *Ann Rheum Dis* 2008 Dec;67(12):1724-31.
- [13] Vital EM, Dass S, Buch MH, Henshaw K, Pease CT, Martin MF, et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. *Arthritis Rheum* 2011 Oct;63(10):3038-47.
- [14] Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. *J Clin Epidemiol* 1996 Dec;49(12):1373-9.
- [15] Higgins JP, Green S. Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (eds) *Cochrane handbook for systematic reviews of interventions* version 5.1.0 [updated March 2011], The Cochrane Collaboration. <http://www.handbook.cochrane.org/>. Published 2011. Accessed 16.06.2016. 2011.
- [16] Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6:e1000097.
- [17] Mendoza-Pinto C, Pirone C, van der Windt DA, Parker B, Bruce IN. Can we identify who gets benefit or harm from mycophenolate mofetil in systemic lupus erythematosus? a systematic review. *Semin Arthritis Rheum* 2017;Forthcoming.
- [18] Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928.

- [19] Pincus T, Miles C, Froud R, Underwood M, Cames D, Taylor S. Methodological criteria for the assessment of moderators in systematic reviews of randomised controlled trials: a consensus study. *BMC Med Res Methodol* 2011;11:14.
- [20] Hayden J, van der Windt DA, Cartwright JL, Cote P, Bombardieri C. Assessing bias in studies of prognostic factors. *Ann Intern Med* 2013;158:280-6.
- [21] Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist GE, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. *J Clin Epidemiol* 2011;64:395-400.
- [22] Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the *Journal of Clinical Epidemiology*. *J Clin Epidemiol* 2011;64:380-2.
- [23] Huguet A, Hayden J, Stinson J, McGrath PJ, Chambers CT, Tougas MA. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. *Syst Rev* 2013;2:71.
- [24] Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. *J Clin Epidemiol* 2011;64:401-6.
- [25] Tew GW, Rabbee N, Wolslegel K, Hsieh HJ, Monroe JG, Behrens TW, et al. Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus. *Lupus* 2010 Feb;19(2):146-57.
- [26] Carter LM, Isenberg DA, Ehrenstein MR. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. *Arthritis Rheum* 2013 Oct;65(10):2672-9.
- [27] Lazarus MN, Turner-Stokes T, Chavele KM, Isenberg DA, Ehrenstein MR. B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels. *Rheumatology (Oxford)* 2012 Jul;51(7):1208-15.
- [28] Lindholm C, Borjesson-Asp K, Zandjanchi K, Sundqvist AC, Tarkowski A, Bokarewa M. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. *J Rheumatol* 2008 May;35(5):826-33.
- [29] Catapano F, Chaudhry AN, Jones RB, Smith KG, Jayne DW. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. *Nephrol Dial Transplant* 2010 Nov;25(11):3586-92.
- [30] Dias SS, Rodriguez-Garcia V, Nguyen H, Pericleous C, Isenberg D. Longer duration of B cell depletion is associated with better outcome. *Rheumatology (Oxford)* 2015 Oct;54(10):1876-81.
- [31] Fernandez-Nebro A, de la Fuente JL, Carreno L, Izquierdo MG, Tomero E, Rua-Figueroa I, et al. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study. *Lupus* 2012 Sep;21(10):1063-76.
- [32] Jonsdottir T, Gunnarsson I, Mourao AF, Lu TY, van Vollenhoven RF, Isenberg D. Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts. *Rheumatology (Oxford)* 2010 Aug;49(8):1502-4.

- [33] Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. *Ann Rheum Dis* 2007 Sep;66(9):1259-62.
- [34] Robledo G, Davila-Fajardo CL, Marquez A, Ortego-Centeno N, Callejas Rubio JL, de Ramon GE, et al. Association between -174 interleukin-6 gene polymorphism and biological response to rituximab in several systemic autoimmune diseases. *DNA Cell Biol* 2012 Sep;31(9):1486-91.
- [35] Robledo G, Marquez A, Davila-Fajardo CL, Ortego-Centeno N, Rubio JL, Garrido ER, et al. Association of the FCGR3A-158F/V gene polymorphism with the response to rituximab treatment in Spanish systemic autoimmune disease patients. *DNA Cell Biol* 2012 Dec;31(12):1671-7.
- [36] Marquez A, Davila-Fajardo CL, Robledo G, Rubio JL, de Ramon GE, Garcia-Hernandez FJ, et al. IL2/IL21 region polymorphism influences response to rituximab in systemic lupus erythematosus patients. *Mol Biol Rep* 2013 Aug;40(8):4851-6.
- [37] Vital EM, Wittmann M, Edward S, Md Yusof MY, MacIver H, Pease CT, et al. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus. *Arthritis Rheumatol* 2015 Jun;67(6):1586-91.
- [38] Cuppen BV, Welsing PM, Sprengers JJ, Bijlsma JW, Marijnissen AC, van Laar JM, et al. Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability. *Rheumatology (Oxford)* 2016 May;55(5):826-39.
- [39] Menon M, Blair PA, Isenberg DA, Mauri C. A Regulatory Feedback between Plasmacytoid Dendritic Cells and Regulatory B Cells Is Aberrant in Systemic Lupus Erythematosus. *Immunity* 2016;44(3):683-97.
- [40] Ezeonyeji AN, Isenberg DA. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen. *Rheumatology (Oxford)* 2012 Mar;51(3):476-81.
- [41] Gracia-Tello B, Ezeonyeji A, Isenberg D. The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness. *Lupus Sci Med* 2017;4(1):e000182.